ライフサイエンスコーパス: genitalium

1 genomes (Buchnera aphidicola and Mycoplasma genitalium).

2 hole-cell model for the bacterium Mycoplasma genitalium.

3 ited availability of diagnostic tests for M. genitalium.

4 e optimal selection of antimicrobials for M. genitalium.

5 d 7 of 10 (70%) participants positive for M. genitalium.

6 ant clinical samples for the detection of M. genitalium.

7 onal repair pathway plays a minor role in M. genitalium.

8 more common among subjects infected with M. genitalium.

9 lammation was highest among subjects with M. genitalium.

10 onserved in other bacteria are missing in M. genitalium.

11 odel and assess endocervical infection by M. genitalium.

12 aginalis, and 47 (9.5%) were positive for M. genitalium.

13 of four geographically diverse strains of M. genitalium.

14 ntly increased the odds of infection with M. genitalium.

15 ine minimum inhibitory concentrations for M. genitalium.

16 widely used to study the epidemiology of M. genitalium.

17 We cloned the genomes of Mycoplasma genitalium (0.6 Mb), M. pneumoniae (0.8 Mb) and M. mycoi

18 ication NAATs targeting unique regions of M. genitalium 16S or 23S rRNA.

19 ification (TMA) NAAT for the detection of M. genitalium 16S rRNA.

20 We observed a high prevalence of M. genitalium (7.4%) among HIV-infected New Orleans women.

21 Mycoplasma genitalium, a human pathogen associated with sexually tr

22 erial vaginosis (BV) and incident Mycoplasma genitalium, a sexually transmitted bacterium associated

23 Mycoplasma genitalium, a sexually transmitted human pathogen, encod

24 h a 3.5-fold increase in odds of incident M. genitalium (adjusted odds ratio = 3.49, 95% confidence i

25 Mice infected with M. genitalium also developed specific antibodies to the maj

26 clinical validation of the Aptima Mycoplasma genitalium (AMG) assay, an in vitro diagnostic (IVD) TMA

27 Screening and treatment of M. genitalium among HIV-infected individuals may be warrant

28 (IVD) TMA test that targets 16 s rRNA of M. genitalium Analytical sensitivity, specificity, and stra

29 termined using nine laboratory strains of M. genitalium and 56 nontarget bacteria, protozoa, and viru

30 le molecular methods for the diagnosis of M. genitalium and assays to predict the antibiotic suscepti

31 Prevalence of M. genitalium and associated genotypic markers of macrolide

32 ecently developed assay can test for both M. genitalium and azithromycin resistance mutations at the

33 infected women for an association between M. genitalium and cervicitis, a putative mechanism for enha

34 ly diverse clinical sites were tested for M. genitalium and for Chlamydia trachomatis, Neisseria gono

35 owing evidence for an association between M. genitalium and HIV genital shedding and the high prevale

36 strong epidemiologic associations between M. genitalium and human immunodeficiency virus (HIV), provi

37 To determine the prevalence of Mycoplasma genitalium and its association with cervical cytology an

38 The relatively high prevalence of Mycoplasma genitalium and its association with prevalent HIV urgent

39 Cases were tested for M. genitalium and macrolide-resistance mutations (MRMs) by

40 Mycoplasma genitalium and other NGU pathogens were detected using n

41 Samples were tested for M. genitalium and other STI organisms (Chlamydia trachomati

42 g data demonstrate an association between M. genitalium and PID, and limited data suggest association

43 ns women, we retrospectively screened for M. genitalium and quantitatively characterized several mark

44 The M. genitalium and T. vaginalis detection rates among 755 pa

45 The associations between M. genitalium and the detection and quantity of genital HIV

46 athways involved in innate recognition of M. genitalium and the response to acute infection in the hu

47 etermine if TMA could also detect Mycoplasma genitalium and Trichomonas vaginalis in men and women re

48 sing the following search terms: (Mycoplasma genitalium) AND (azithromycin OR zithromax OR [treatment

49 nsion of the STI analyte panel (including M. genitalium) and additional specimen source sampling with

50 achomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis infections as well

51 ibly small-two to four times smaller than M. genitalium-and these tiny genomes have raised questions

52 Mycoplasma pneumoniae and Mycoplasma genitalium are closely related organisms that cause dist

53 There is increasing concern about Mycoplasma genitalium as a cause of urethritis, cervicitis, pelvic

54 scovery, microbiology, and recognition of M. genitalium as a pathogen, and then summarize the recent

55 These findings implicate M. genitalium as an etiologic agent of cervicitis in HIV-in

56 ns, and the literature supporting Mycoplasma genitalium as an etiology of urethritis is growing.

57 ears, were tested with the Aptima Mycoplasma genitalium assay, an investigational transcription-media

58 Administration-approved clinical test for M. genitalium available in the United States at this time.

59 cid amplification test (NAAT) for Mycoplasma genitalium, B.

60 cumulative PID incidence in women due to M. genitalium by 31.1% (95% range:13.0%-52.0%) over 20 year

61 MsrA affects the virulence properties of M. genitalium by modulating its interaction with host cells

62 m women every other month were tested for M. genitalium by nucleic acid amplification testing.

63 o Statens Serum Institut for detection of M. genitalium by polymerase chain reaction between 1 Januar

64 field, the positive predictive values for M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vagin

65 Here, we report that M. genitalium can establish long-term infection of human en

66 provide strong experimental evidence that M. genitalium can establish long-term infection of reproduc

67 The evidence that M. genitalium causes epididymo-orchitis, proctitis, and rea

68 Mycoplasma genitalium causes persistent urogenital tract infection

69 cquiring STIs, the prevalences of Mycoplasma genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae

70 Specimens were tested for M. genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae

71 Chlamydia trachomatis and Mycoplasma genitalium coinfections were evaluated using nucleic aci

72 V) infection revealed 19 (18.6%) cases of M. genitalium, commonly (58%) in rectal samples.

73 The DNA genome of Mycoplasma genitalium currently represents the smallest of all know

74 idence for the first FDA-cleared NAAT for M. genitalium detection in the United States.

75 was no evidence of an association between M. genitalium detection or quantity and either plasma HIV-1

76 A 10.0% M. genitalium detection rate from other facilities exceeded

77 ch as the emergent human pathogen Mycoplasma genitalium, developed a complex polar structure, known a

78 g the search terms Mycoplasma genitalium, M. genitalium, diagnosis, and detection.

79 as a comparator for the validation of new M. genitalium diagnostic tests.

80 Typing assigned M. genitalium DLSTs to 2 major clusters, broadly distribute

81 ve polymerase chain reaction specific for M. genitalium DNA on samples 14-100 days post-treatment.

82 at and performance indices of a number of M. genitalium DNA- and RNA-based amplification assays; many

83 e and inflammation signature activated by M. genitalium during acute infection (48 hours after inocul

84 on-mediated amplification (TMA) tests for M. genitalium, each targeting unique rRNA sequences, for us

85 y, we demonstrate that surface-associated M. genitalium EF-Tu (EF-Tu(Mg)), in spite of sharing 96% id

86 ns, understanding the mechanisms by which M. genitalium elicits mucosal inflammation is an essential

87 The human pathogen Mycoplasma genitalium employs homologous recombination to generate

88 identified STI involved sole detection of M. genitalium Expansion of the STI analyte panel (including

89 Here, we show that M. genitalium expresses N-terminally truncated RecA isoform

90 doxycycline for presumptive treatment of M. genitalium, followed by resistance-guided therapy, cured

91 Recovery of viable M. genitalium from lower genital tract specimens was improv

92 The complete synthetic Mycoplasma genitalium genome ( approximately 583 kb) has been assem

93 The Mycoplasma genitalium genome has historically defined the extreme s

94 y of recombination genes conserved in the M. genitalium genome.

95 Several novel M. genitalium genotypes were identified, all of which were

96 s of sequential antimicrobial therapy for M. genitalium guided by a macrolide-resistance assay.

97 Escherichia coli, inactivation of recA in M. genitalium had a minimal effect on survival after exposu

98 Testing for M. genitalium has become important for clinicians treating

99 available, and their use in screening for M. genitalium has been advocated, but M. genitalium's natur

100 Infection with Mycoplasma genitalium has been associated with male and female urog

101 Mycoplasma genitalium has been causally linked with nongonococcal u

102 Mycoplasma genitalium has been significantly and nonsignificantly a

103 Since M. genitalium has the capacity to invade eukaryotic cells a

104 However, diagnostic assays for M. genitalium have been limited in the United States.

105 eening programs and targeted treatment of M. genitalium improve reproductive outcomes in women are ne

106 al and extragenital screening for Mycoplasma genitalium in 102 asymptomatic Air Force members with hu

107 from Johannesburg (2012) detected Mycoplasma genitalium in 7.4% (95% confidence interval [CI]: 5.5-9.

108 mprehensive testing programs would detect M. genitalium in a significant proportion of females, parti

109 The importance of Mycoplasma genitalium in human immunodeficiency virus (HIV)-burdene

110 Although the pathogenic role of Mycoplasma genitalium in male urethritis is clear, fewer studies ha

111 Mycoplasma genitalium in our study displayed the clinical features

112 roduced evidence for at least two Mycoplasma genitalium in silico minimal genomes.

113 nd the high prevalence and persistence of M. genitalium in this population suggest that further resea

114 al specimens for the detection of Mycoplasma genitalium in women by using our laboratory-developed PC

115 Factors associated with prevalent Mycoplasma genitalium, including sociodemographics, reproductive hi

116 aled reinfection by a different strain of M. genitalium, indicating the absence of protective immunit

117 igh azithromycin failure rate (39%) in an M. genitalium-infected cohort in association with high leve

118 The mean age of the M. genitalium-infected females (24.7 years) was lower than

119 Consecutive eligible M. genitalium-infected men and women attending the Melbourn

120 gimens in a prospective cohort of Mycoplasma genitalium-infected participants, and factors associated

121 ]), C. trachomatis (11.7 [2.3-58.9]), and M. genitalium infection (9.6 [3.1-29.9]) were associated wi

122 en was also significantly associated with M. genitalium infection (OR = 2.97; 95% CI = 2.14 to 4.13).

123 At baseline, 16.1% had prevalent M. genitalium infection and 40.4% had prevalent BV.

124 determine the association between Mycoplasma genitalium infection and female reproductive tract syndr

125 quence variation in patients with chronic M. genitalium infection and to analyze the sequence structu

126 es assessing associations with persistent M. genitalium infection are needed.

127 employed to estimate the odds of incident M. genitalium infection at follow-up visits among women wit

128 toms had a significantly elevated risk of M. genitalium infection compared to that for asymptomatic i

129 Therefore, persistent M. genitalium infection could have important consequences f

130 Diagnosis of M. genitalium infection is recommended using a nucleic acid

131 and N. gonorrhoeae infections, while the M. genitalium infection rate in males was significantly hig

132 Cure of M. genitalium infection resulted in ablation of all signs o

133 ng care in the United States suggest that M. genitalium infection should be considered in young perso

134 se during menses were less likely to have M. genitalium infection than those who did not (odds ratio

135 and cervicitis had a higher prevalence of M. genitalium infection than women without those diagnoses,

136 e participants, the overall prevalence of M. genitalium infection was 10.3% and was significantly hig

137 Chronic M. genitalium infection was associated with increased secre

138 The risk for M. genitalium infection was higher in black than in white p

139 Mycoplasma genitalium infection was less prevalent in older women (

140 Mycoplasma genitalium infection was significantly associated with i

141 l STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infection) was lower in the intervention arm,

142 nfection, and 0.66 [95% CI, .38-1.15] for M. genitalium infection).

143 female pig-tailed macaques as a model of M. genitalium infection, persistence, and immune evasion.

144 re analyzed to describe the prevalence of M. genitalium infection, risk factors, and disease associat

145 female pig-tailed macaque as a model for M. genitalium infection, we cervically inoculated eight add

146 tability of a pig-tailed macaque model of M. genitalium infection, we inoculated a pilot animal with

147 nely screening any defined population for M. genitalium infection.

148 matis, Neisseria gonorrhoeae, and Mycoplasma genitalium infection.

149 sts that BV may enhance susceptibility to M. genitalium infection.

150 Of 244 evaluable M. genitalium infections (52 women, 68 heterosexual men, 12

151 There were 59 incident M. genitalium infections among 50 women, for an incidence r

152 igations into the causal relationships of M. genitalium infections and clinical disease have been hin

153 The prevalence rates of Mycoplasma genitalium infections and coinfections with other sexual

154 ly whether screening for and treatment of M. genitalium infections in women and their sexual partners

155 % credible interval, .4-14.1%) of Mycoplasma genitalium infections in women progress to pelvic inflam

156 Significant risk factors for M. genitalium infections were black race, younger age, non-

157 Female M. genitalium infections were significantly more prevalent

158 ve useful in management of some resistant M. genitalium infections, although it is not likely to achi

159 n, have been the treatments of choice for M. genitalium infections.

160 stinguished asymptomatic from symptomatic M. genitalium infections.

161 vent the emergence of ever more resistant M. genitalium infections.

162 Mycoplasma genitalium is a common cause of nongonococcal urethritis

163 Mycoplasma genitalium is a common sexually transmitted infection as

164 Mycoplasma genitalium is a frequent undiagnosed cause of NGU in thi

165 Mycoplasma genitalium is a human bacterial pathogen linked to ureth

166 Because Mycoplasma genitalium is a prevalent and emerging cause of sexually

167 Mycoplasma genitalium is a sexually transmitted bacterium linked to

168 Mycoplasma genitalium is a sexually transmitted pathogen associated

169 Antimicrobial-resistant M. genitalium is a significant problem and may require clin

170 Mycoplasma genitalium is an emerging sexually transmitted pathogen

171 Mycoplasma genitalium is an emerging sexually transmitted pathogen

172 Mycoplasma genitalium is an important and emerging agent of sexuall

173 Mycoplasma genitalium is an important sexually transmitted pathogen

174 Mycoplasma genitalium is an underappreciated cause of human reprodu

175 Because M. genitalium is associated with both HIV acquisition and t

176 M. genitalium is difficult to culture, and in the absence o

177 Mycoplasma genitalium is expected to metabolize RNA using unique pa

178 The prevalence of Mycoplasma genitalium is high in vulnerable populations of women in

179 Mycoplasma genitalium is increasingly appreciated as a common cause

180 Although Mycoplasma genitalium is increasingly recognized as a sexually tran

181 roquinolone treatment failure for Mycoplasma genitalium is poorly understood.

182 cubation period for NGU caused by Mycoplasma genitalium is probably longer than for NGU caused by C.

183 Mycoplasma genitalium is the smallest self-replicating bacterium an

184 Mycoplasma genitalium is the smallest self-replicating organism and

185 Mycoplasma genitalium is very difficult to grow in culture but has

186 region of MG192 was amplified by PCR from M. genitalium isolates obtained at various time points post

187 ve previously shown that a mutant form of M. genitalium lacking methionine sulfoxide reductase A (Msr

188 B and MgpC, but was insufficient to clear M. genitalium lower tract infection.

189 and 2016, using the search terms Mycoplasma genitalium, M. genitalium, diagnosis, and detection.

190 esting of high-risk symptomatic women for M. genitalium may be warranted.

191 Some studies suggest that M. genitalium may increase the risk of HIV acquisition.

192 Chlamydia trachomatis (CT) and Mycoplasma genitalium (MG) are two highly prevalent bacterial sexua

193 Macrolide-resistance in Mycoplasma genitalium (MG) exceeds 50% in many regions and quinolon

194 Macrolide resistance in Mycoplasma genitalium (MG) exceeds 50% in many regions, and quinolo

195 ia trachomatis (CT) in 13 (9.0%), Mycoplasma genitalium (MG) in 4 (2.8%), HPV16 in 38 (26.2%), HPV52

196 Mycoplasma genitalium (MG) infections are a growing concern within

197 Although Mycoplasma genitalium (MG) is an acknowledged cause of nongonococca

198 Mycoplasma genitalium (MG) is an emerging pathogen among men who ha

199 Mycoplasma genitalium (MG) is an emerging sexually transmitted infe

200 Mycoplasma genitalium (MG) is associated with nongonococcal urethri

201 Antimicrobial resistance in Mycoplasma genitalium (MG), a cause of urethritis, is a growing con

202 Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), and Trichomonas vaginalis (TV) are sexu

203 d for Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Ureaplasma urealyticum biovar 2 (UU-2),

204 An M. genitalium mutant lacking the MG491 segment correspondin

205 factors of Gardnerella vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, S

206 olide and quinolone resistance in Mycoplasma genitalium necessitate new treatment approaches.

207 es of MG_186, a calcium-dependent Mycoplasma genitalium nuclease.

208 arise from the introduction of diagnostic M. genitalium nucleic acid amplification testing including

209 are needed to better define the impact of M. genitalium on women's reproductive health.

210 s among subjects with monoinfections with M. genitalium or C. trachomatis compared to women with no d

211 h at most time points the median ratio of M. genitalium organisms to host cells was </=10, indicating

212 sequence analysis of single-colony cloned M. genitalium organisms.

213 (STI), 35.9% exhibited sole detection of M. genitalium (P </= 0.0004 versus sole detection of other

214 (Neisseria gonorrhoeae, P = .03; Mycoplasma genitalium, P = .04; HSV-2, P = .001; and a trend for Ch

215 h failure we sequenced key regions of the M. genitalium parC and gyrA genes for patients undergoing s

216 iled macaque is a suitable model to study M. genitalium pathogenesis, antibody-mediated selection of

217 In the upper tract, more than 90% of M. genitalium PCR-positive samples were from the uterus and

218 Viable M. genitalium persisted in the lower genital tract for 8 we

219 Genetic diversity of M. genitalium populations was determined to infer whether f

220 6.8% of women and 15.1% of men were found M. genitalium positive.

221 nce was detected in 38% (385/1008) of the M. genitalium-positive patients, and the highest rate was f

222 ess macrolide antibiotic resistance among M. genitalium-positive subjects.

223 Our results also suggest that M. genitalium possesses an active nucleotide excision repai

224 Surveillance of M. genitalium prevalence and antimicrobial resistance patte

225 M. genitalium prevalence rates were 16.1% for females and 1

226 M. genitalium prevalence was 10.2% in females and 10.6% in

227 Among 217 men, M. genitalium prevalence was 16.7% (95% confidence interval

228 Analytical sensitivity of the tests for M. genitalium ranged from 0.017 to 0.040 genome equivalents

229 The specificity of the cobas assay for M. genitalium ranged from 96.0% to 99.8% across symptomatic

230 We conclude that M. genitalium RecA has a primary role in mgpB/C-MgPar recom

231 s out the research priorities for Mycoplasma genitalium research agreed upon by the participants in a

232 esidual material was subjected to Mycoplasma genitalium research-use-only TMA.

233 Positive M. genitalium results were confirmed by repeat testing or a

234 atment, and public health significance of M. genitalium reviewed at the meeting is described in detai

235 Therefore, M. genitalium RNase R can precisely remove the 3'-trailer o

236 at the only exoribonuclease identified in M. genitalium, RNase R, is able to remove tRNA 3'-trailers

237 d these studies by examining the roles of M. genitalium ruvA and ruvB homologs.

238 o improve understanding of key aspects of M. genitalium's natural history before it will be possible

239 for M. genitalium has been advocated, but M. genitalium's natural history is poorly-understood, makin

240 owever, there is important uncertainty in M. genitalium's natural history parameters, leading to unce

241 behavioural studies to better understand M. genitalium's natural history, and then examined the effe

242 Mycoplasma genitalium samples from cases failing moxifloxacin were

243 itional Trichomonas vaginalis and Mycoplasma genitalium screening found 17.4% and 23.9% of the encoun

244 onsideration of the cost-effectiveness of M. genitalium screening interventions may be warranted.

245 test (NAAT) for the detection of Mycoplasma genitalium Seven urogenital specimen types (n = 11,556)

246 These results show a high prevalence of M. genitalium single infections, a lower prevalence of coin

247 variation occurred during the process of M. genitalium single-colony cloning.

248 M. genitalium-specific IgG, but not IgA, was detected in ce

249 M. genitalium-specific serum antibodies targeting the immun

250 MG192 sequences were more related within M. genitalium specimens from an individual patient than bet

251 lium virulence, we compared the wild-type M. genitalium strain (G37) with an msrA mutant (MS5) strain

252 ection, we inoculated a pilot animal with M. genitalium strain G37 in the uterine cervix and in salpi

253 cimens from two chimpanzees infected with M. genitalium strain G37.

254 terial pathogens, genomic diversity among M. genitalium strains worldwide is unknown.

255 all viable single-gene disruption Mycoplasma genitalium strains.

256 ese correlates differ from those found in M. genitalium studies conducted with FSW from West Africa a

257 ved except with superphysiologic loads of M. genitalium, suggesting that persistent infection occurs

258 e in a 5-year period where all diagnostic M. genitalium testing in Denmark was centralized at the Sta

259 tablish the cost-effectiveness of routine M. genitalium testing in symptomatic patients and screening

260 alth agencies should consider integrating M. genitalium testing into the management of persons with s

261 The aim of the study was to analyze the M. genitalium testing pattern and distribution of positive

262 use were more likely to be infected with M. genitalium than those who reported less frequent use (OR

263 life cycle of the human pathogen Mycoplasma genitalium that includes all of its molecular components

264 tion remains poorly understood in Mycoplasma genitalium, the smallest self-replicating cell and the c

265 Incorporation of M. genitalium TMA into comprehensive testing programs would

266 This study highlights the capacity of M. genitalium to elicit cervical inflammation and, consider

267 Is and BV, there was a positive trend for M. genitalium to predict cervicitis (AOR, 3.18 [95% confide

268 Attachment of M. genitalium to the host cell's apical surface was observe

269 In addition, dissemination of M. genitalium to the knee tissues was observed as early as

270 Mycoplasma genitalium treatment failure was extremely common.

271 norrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, adenovirus, and herpe

272 l and then inoculated intravaginally with M. genitalium type strain G37 or a contemporary Danish stra

273 han a single 1g dose at achieving cure of M. genitalium urethritis and importantly did not reduce the

274 e and new approaches for the treatment of M. genitalium urethritis are required.

275 microbiological cure in men with Mycoplasma genitalium urethritis during 2013-2015 and compared this

276 ological cure was determined for men with M. genitalium urethritis treated with azithromycin 1.5g usi

277 orkers in Kampala were tested for Mycoplasma genitalium using a commercial Real-TM polymerase chain r

278 se of the Gram-positive bacterium Mycoplasma genitalium using over 900 sources.

279 were tested for detection and quantity of M. genitalium using polymerase chain reaction analysis.

280 TV)/MG assay (cobas) for the detection of M. genitalium, using 22,150 urogenital specimens from both

281 nto the mechanisms by which MsrA controls M. genitalium virulence, we compared the wild-type M. genit

282 The prevalence of M. genitalium was 12.9%.

283 The prevalence of Mycoplasma genitalium was 14% and higher in HIV-positive women than

284 M. genitalium was also less prevalent among FSW who had wor

285 Mycoplasma genitalium was associated with Neisseria gonorrhoeae (ad

286 M. genitalium was detected in 10.5% of stored specimens (44

287 M. genitalium was detected in 282 (11.4%) patients.

288 M. genitalium was independently associated with detection o

289 Among 400 women studied, M. genitalium was independently significantly associated wi

290 n-PCR showed that expression of MG_454 in M. genitalium was not elevated in response to oxidative str

291 inoculated in salpingeal pockets, viable M. genitalium was recovered for 2 weeks.

292 Using a novel quantitative PCR assay, M. genitalium was shown to replicate from 0 to 80 days post

293 ce building a whole-cell model of Mycoplasma genitalium, we identified several significant challenges

294 tion in vitro diagnostic test for Mycoplasma genitalium were analyzed to describe the prevalence of M

295 f 22 (41%; 95% CI, 20%-62%) patients with M. genitalium were infected with DLSTs possessing genotypic

296 med at Chlamydia trachomatis, but Mycoplasma genitalium, which also commonly causes undiagnosed NGU,

297 ional organization of the RuvAB system of M. genitalium, which is cotranscribed with two novel open r

298 ells, MG_186 has the potential to provide M. genitalium, which possesses the smallest genome of any s

299 This study examined the associations of M. genitalium with selected sexually transmitted infections

300 mens from 28 958 patients were tested for M. genitalium, with an increasing trend from 3858 per year